Cardiovascular implants market seen reaching $39.09 billion by 2030

The cardiovascular implants market is projected to grow from $28.68 billion in 2025 to $30.52 billion in 2026, then reach $39.09 billion by 2030, according to The Business Research Company. Demand is being driven by rising heart disease rates, more minimally invasive cardiac procedures and broader use of advanced implant materials and devices.

Why it matters: - The cardiovascular implants market sits at the center of treatment for blocked arteries, irregular heart rhythms and valve problems. - Rising disease burden and faster adoption of advanced cardiac devices are expanding demand for stents, pacemakers and heart valve technologies. - The market’s projected climb to $39.09 billion by 2030 signals continued spending on cardiac care infrastructure and implant innovation.

What happened: - The Business Research Company released a cardiovascular implants market intelligence report on July 30, 2026. - The report projects the market will rise from $28.68 billion in 2025 to $30.52 billion in 2026. - The report says the market will grow at a 6.4% compound annual growth rate through 2030. - North America held the largest share of the market in 2025.

The details: - Cardiovascular implants are surgically placed devices used to restore heart function and improve blood flow. - The category includes implants used for blocked arteries, heart rhythm disorders and valve malfunctions. - The report links historical growth to higher cardiovascular disease rates, more interventional cardiology procedures, expansion of hospital cardiac care units, wider use of implantable pacemakers and access to advanced biomaterials. - The market is forecast to benefit from an aging population, greater preference for minimally invasive cardiac treatments, broader use of structural heart disease therapies, personalized cardiovascular care and ongoing innovation in implant designs and materials. - The report highlights growing adoption of minimally invasive implants, drug-eluting and bioabsorbable stents, transcatheter heart valve procedures, cardiac rhythm management devices and longer-lasting implants. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 report package includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, key technology analysis and future trend analysis. - The company offers a free sample report and the full market report.

Between the lines: - The report points to a market shaped by both medical need and technology upgrades, which usually favors suppliers with strong device pipelines and clinical differentiation. - North America’s lead suggests the largest near-term revenue base remains in mature healthcare systems, while faster percentage growth may come from regions increasing investment in cardiac care. - The emphasis on minimally invasive and longer-lasting devices shows a shift toward procedures that can reduce recovery time and repeat interventions. - British Heart Foundation data cited in the report shows about 7.6 million people in the UK had heart and circulatory diseases in September 2024, with projections rising by 1 million by 2030 and by 2 million more by 2040.

What's next: - The market is expected to keep expanding as healthcare systems respond to aging populations and higher rates of cardiovascular disease. - Continued product development in stents, valves and rhythm management devices is likely to shape competitive positioning through 2030. - Regions outside North America may capture more growth if healthcare investment and access to cardiac procedures continue to rise.

The bottom line: - Cardiovascular implants remain a growth market because heart disease prevalence is rising and treatment is shifting toward more advanced, less invasive devices.